AITL with HRS-like cells is prone to misdiagnosis as CHL due to overlapping morphological and immunophenotypic features. Integration of EBER, TCR/IG clonality assessment, and molecular profiling, particularly the identification of TET2 and RHOA mutations is essential for accurate classification. Recognizing this entity is critical for avoiding diagnostic pitfalls and guiding appropriate therapeutic strategies.

7 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

DNMT3A (DNA methyltransferase 1) • PD-1 (Programmed cell death 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CREBBP (CREB binding protein) • PAX5 (Paired Box 5) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • RHOA (Ras homolog family member A) • MME (Membrane Metalloendopeptidase) • BRD4 (Bromodomain Containing 4)

TET2 mutation • TNFRSF8 positive • TNFRSF8 expression

CART-30

11d

LCCC 1606-ATL: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (clinicaltrials.gov)

P1, N=43, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2041 --> Nov 2039 | Trial primary completion date: Sep 2026 --> Dec 2025

11 days ago

Enrollment closed • Trial completion date • Trial primary completion date

TNFRSF8 (TNF Receptor Superfamily Member 8) • CCR4 (C-C Motif Chemokine Receptor 4)

TNFRSF8 positive • TNFRSF8 expression

bendamustine • fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells

17d

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)

P1/2, N=38, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Aug 2038 --> Nov 2039 | Trial primary completion date: Sep 2027 --> Dec 2025

17 days ago

Enrollment closed • Trial completion date • Trial primary completion date

TNFRSF8 (TNF Receptor Superfamily Member 8)

TNFRSF8 expression

TT11

25d

Optimization of velocity receptor transduction in CAR T cells. (PubMed, bioRxiv)

We also observed a log-linear relationship between viral dose and transduction efficiency for a subset of VRs previously tested in various mouse models of human cancer, with VR5αIL8 and VR5αTNFα VRs consistently outperforming VR5αIL5 and V5 (full length native IL5 receptor). Overall, these findings establish an optimized and reproducible framework that offers valuable guidance for the future development and functional study of VR-CAR T cells in cellular therapies for solid tumors.

25 days ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL5 (Interleukin 5)

28d

CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)

P2, N=2, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=18 --> 2 | Trial completion date: Aug 2030 --> Dec 2030 | Trial primary completion date: Sep 2026 --> Dec 2025

28 days ago

Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date

cyclophosphamide • fludarabine IV • TT11

CABAL2: Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (clinicaltrials.gov)

P1, N=90, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting

1 month ago

Enrollment open

TT11X

2ms

CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)

P2, N=18, Recruiting, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2025 --> Sep 2026

2 months ago

Enrollment open • Trial primary completion date

cyclophosphamide • fludarabine IV • TT11

5ms

CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)

P2, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Aug 2030 | Trial primary completion date: Dec 2026 --> Sep 2025

5 months ago

Enrollment closed • Trial completion date • Trial primary completion date

cyclophosphamide • fludarabine IV • TT11

5ms

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)

P1, N=18, Recruiting, Baylor College of Medicine | Trial primary completion date: Jun 2025 --> Jun 2026

5 months ago

Trial primary completion date

ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)

ALK positive • TNFRSF8 positive • ALK negative

TT11X

7ms

Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma. (PubMed, Front Immunol)

The patient received two doses of anti-CD20/CD30-CAR-T therapy administered one month apart...The report underscores the promising therapeutic potential and safety profile of CD20/CD30-directed CAR T-cell therapy. https://www.clinicaltrials.gov, identifier NCT06756321.

7 months ago

Journal

TNFRSF8 (TNF Receptor Superfamily Member 8)

10ms

CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma (clinicaltrials.gov)

P=N/A, N=15, Recruiting, Shanxi Bethune Hospital

10 months ago

New trial

TNFRSF8 (TNF Receptor Superfamily Member 8)

11ms

HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA. (PubMed, Blood)

Our study shows that selection of the epitope targeting CD30 and ex vivo preservation of less-differentiated memory T cells may enhance the efficacy of CART30 in patients with refractory HL. This trial is registered at www.clinicaltrials.gov (NCT04653649).

11 months ago

Journal

TNFRSF8 (TNF Receptor Superfamily Member 8) • IL15 (Interleukin 15) • IL21 (Interleukin 21) • IL7 (Interleukin 7)